Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups - Université de Lorraine Access content directly
Journal Articles Blood Cancer Journal Year : 2016

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

Remi Letestu
  • Function : Author
  • PersonId : 1011449
Fichier principal
Vignette du fichier
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10.pdf (380.36 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-01666834 , version 1 (03-02-2020)

Licence

Attribution

Identifiers

Cite

Anne-Laure Gagez, Émilie Tuaillon, R Cezar, Caroline Dartigeas, B Mahé, et al.. Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups. Blood Cancer Journal, 2016, 6 (1), pp.e389. ⟨10.1038/bcj.2015.115⟩. ⟨hal-01666834⟩
287 View
147 Download

Altmetric

Share

Gmail Facebook X LinkedIn More